Rifaximin effective for repeat treatment of IBS with diarrhea

December 27, 2016

(HealthDay)—Repeat treatment with the nonsystemic antibiotic rifaximin is effective in patients with relapsing symptoms of diarrhea-predominant irritable bowel syndrome (IBS-D), according to a study published in the December issue of Gastroenterology.

Anthony Lembo, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues conducted a multicenter, phase 3, randomized, placebo-controlled trial to evaluate the safety and efficacy of repeat with the nonsystemic antibiotic rifaximin (550 mg three times daily for two weeks) among 636 adults with IBS-D, mean and bloating scores of 3 or more, and loose stool (February 2012 through June 2014).

The researchers found that the percentage of responders was significantly greater with rifaximin than placebo (P = 0.03). For abdominal pain, the percentage of responders (P = 0.018) was significantly greater with rifaximin versus placebo, but not for stool consistency (P = 0.42). There were also significant improvements for prevention of recurrence, durable response, and urgency. The groups had similar adverse event rates.

"In a phase 3 study of patients with relapsing symptoms of IBS-D, repeat rifaximin treatment was efficacious and well tolerated," the authors write.

Several authors disclosed financial ties to Salix Pharmaceuticals, which manufactures rifaximin and funded the study.

Explore further: Low-dose rifaximin cuts endotoxin level in cirrhosis

More information: Full Text

Related Stories

Low-dose rifaximin cuts endotoxin level in cirrhosis

October 29, 2015
(HealthDay)—For patients with liver cirrhosis, low-dose rifaximin is comparable to high-dose rifaximin for reducing serum endotoxin levels, according to a study published online Oct. 16 in the Journal of Digestive Diseases.

FDA approves new drugs for irritable bowel syndrome

May 28, 2015
(HealthDay)—Two new drugs for adults with irritable bowel syndrome with diarrhea (IBS-D) were approved by the U.S. Food and Drug Administration on Wednesday.

Relamorelin beneficial in adults with diabetic gastroparesis

July 7, 2016
(HealthDay)—For adults with diabetic gastroparesis, relamorelin reduces vomiting frequency and severity and accelerates gastric emptying, according to a study published in the July issue of Gastroenterology.

Targeted antibiotic drug safest among recommended treatments for irritable bowel disease

November 2, 2011
Among the most commonly used treatments for irritable bowel syndrome – which affects as many as 20 percent of the United States population – a targeted antibiotic was shown to be the safest in a new study by Cedars-Sinai ...

Recommended for you

Largest oral HPV study in England shows infection rates lower than expected

August 20, 2018
Infection rates of high risk human papillomavirus (HR-HPV) oral infection in England are lower than expected, compared to previous US studies.

Tibetan sheep highly susceptible to human plague, originates from marmots

August 16, 2018
In the Qinghai-Tibet plateau, one of the region's highest risk areas for human plague, Himalayan marmots are the primary carriers of the infectious bacterium Y. pestis. Y. pestis infection can be transmitted to humans and ...

Autoimmunity plays role in development of COPD, study finds

August 16, 2018
Autoimmunity plays a role in the development of chronic obstructive pulmonary disease (COPD), according to a study led by Georgia State University and Vanderbilt University Medical Center that analyzed human genome information ...

Reliable point-of-care blood test can help prevent toxoplasmosis

August 16, 2018
A recent study, performed in Chicago and Rabat, Morocco, found that a novel finger-prick test for infection with the parasite Toxoplasma gondii during pregnancy—and many other potential applications—is 100 percent sensitive ...

Scientists identify nearly 200 potential tuberculosis drug targets

August 16, 2018
Tuberculosis is one of the top 10 causes of death worldwide. Nearly 2 million people die every year from this infectious disease, and an estimated 2 billion people are chronically infected. The only vaccine, developed almost ...

First mouse model to mimic lung disease could speed discovery of more effective treatments

August 16, 2018
The biggest hurdle to finding effective therapies for idiopathic pulmonary fibrosis (IPF) – a life-threatening condition in which the lungs become scarred and breathing is increasingly difficult – has been the inability ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.